HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy

Lung Cancer

Volumn 48, Issue 1, 2005, Pages 59-67

  Junker, Klaus ^a   Stachetzki, Ulf ^a   Rademacher, Daniela ^a   Linder, Albert ^b   Macha, Hans Nicol ^b   Heinecke, Achim ^c   Müller, Klaus Michael ^a   Thomas, Michael ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Lung Hospital   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

FISH; HER2 neu (p185 neu); Hercep Test; Neoadjuvant therapy; Non small cell lung cancer; Therapy induced tumor regression

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION;

EID: 15044341616     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.10.010     Document Type: Article

References (31)

1. D.M. Parkin, F.I. Bray, and S.S. Devesa Cancer burden in the year 2000. The global picture Eur J Cancer 37 2001 4 66
2. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717
3. D.H. Johnson, A.T. Turrisi, and H.I. Pass Combined modality treatment for locally advanced non-small cell lung cancer H.I. Pass J.B. Mitchell D.H. Johnson Lung cancer: principles and practice 1996 Lippincott New York 863 873
4. F.R. Hirsch, W.A. Franklin, R. Veve, M. Varella-Garcia, and P.A. Bunn HER2/neu expression in malignant lung tumors Semin Oncol 29 2002 51 58
5. NEU Eur Respir J 13 1999 424 429
6. C.M. Tsai, K.T. Chang, R.P. Perng, T. Mitsudomi, M.H. Chen, and C. Kadoyama Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations J Natl Cancer Inst 85 1993 897
7. A.H. Bowker Bowker's test for symmetry J Am Stat Assoc 43 1948 572 574
8. D.B. Weiner, J. Nordberg, and R. Robinson Expression of the neu gene encoded protein (185neu) in human non-small cell carcinomas of the lung Cancer Res 50 1990 421 425
9. J.A. Kern, D.A. Schwartz, and J.E. Nordberg p185neu expression in human lung adenocarcinomas predicts shortened survival Cancer Res 50 1990 5184 5187
10. M. Tateishi, T. Ishida, T. Mitsudomi, S. Kaneko, and K. Sugimachi Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma Eur J Cancer 27 1991 1372 1375
11. D. Shi, G. He, and S. Cao Overexpression of the c-erbB2/neu-encoded p185 protein in primary lung cancer Mol Carcinog 5 1992 213 218
12. J.A. Kern, R.J.C. Slebos, B. Top, S. Rodenhuis, D. Lager, and R.A. Robinson C-erb B-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas J Clin Invest 93 1994 516 520
13. M. Diez, M. Pollan, and A. Torres Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue Br J Cancer 75 1997 684 689
14. M. Thomas, C. Rübe, M. Semik, M. van Eiff, L. Freitag, and H.N. Macha Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small cell lung cancer J Clin Oncol 17 1999 1185 1193
15. G. Cox, M. Vyberg, B. Melgaard, J. Askaa, A. Oster, and K.J. O'Byrne Herceptest: Her2 expression and gene amplification in non-small cell lung cancer Int J Cancer 92 2001 480 483
16. D. Scheurle, M. Jahanzeb, R.S. Aronsohn, L. Watzek, and R. Narayanan Her2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep-Test Anticancer Res 20 2000 2091 2096
17. P.A. Bunn Jr., B. Helfrich, A.F. Soriano, W.A. Franklin, M. Varella-Garcia, and F.R. Hirsch Expression of Her2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents Clin Cancer Res 7 2001 3239 3250
18. R.G. Zinner, B.S. Glisson, F.V. Fossella, K.M. Pisters, M.S. Kies, and E. Massarelli Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease Lung Cancer 44 1 2004 99 110
19. S.L. Graziano, A. Tatum, J.E. Herndon 2nd, J. Box, V. Memoli, and M.R. Green Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non -small cell lung cancer: a cancer and leukemia group B study Lung Cancer 33 2001 115 123
20. K.R. Brooks, K. To, M.B. Joshi, D.H. Conlon, J.E. Herndon 2nd, and T.A. D'Amico Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection Ann Thorac Surg 76 1 2003 187 193
21. K. Junker, M. Thomas, K. Schulmann, F. Klinke, U. Bosse, and K.M. Müller Tumor regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment J Cancer Res Clin Oncol 123 1997 469 477
22. K. Junker, K. Langner, F. Klinke, U. Bosse, and M. Thomas Grading of tumor regression in non-small cell lung cancer: morphology and prognosis Chest 120 2001 1584 1591
23. D. Gancberg, A. Di Leo, F. Cardoso, G. Rouas, M. Pedrocchi, and M. Paesmans Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 2002 1036 1043
24. K. Akita, H. Maeda, T. Niimi, H. Kawaguchi, S. Ninomiya, and Y. Yamada P185-HER-2/neu and p21-WAF1/CIPI expression in primary tumor and metastatic lymph node in non-small cell lung cancer Am J Respir Crit Care Med 163 2001 A68
25. C.M. Tsai, D. Yu, K.T. Chang, L.H. Wu, R.P. Perng, and N.K. Ibrahim Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells J Natl Cancer Inst 87 1995 682 684
26. L. Zhang, and M.C. Hung Sensitisation of Her2/neu-overexpressing non-small cell lung cancer cells to chemotherapy drugs by tyrosine kinase inhibitor emodin Oncogene 12 1996 571 576
27. C.M. Tsai, A. Levitzki, L.H. Wu, K.T. Chang, C.C. Cheng, and A. Gazit Enhancement of chemosensitivity by tyrphostin AG825 in high-p185neu expressing non-small cell lung cancer cells Cancer Res 56 1996 1068 1074
28. C.M. Tsai, K.T. Chung, L. Li, R.P. Perng, and L.Y. Yung Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, Her-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells Jpn J Cancer Res 91 2000 213 222
29. R. Pietras, B.M. Fendly, V.R. Chazin, M.D. Pegrum, S.B. Howell, and D.J. Slamon Antibody to HER2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells Oncogene 9 1994 1829 1838
30. L. Yen, Z.R. Nie, X.L. You, S. Richard, B.C. Langton-Webster, and M.A. Alaoui-Jamali Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway Oncogene 14 1997 1827 1835
31. C.M. Tsai, K.T. Chang, J.Y. Chen, Y.M. Chen, M.H. Chen, and R.P. Perng Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu Cancer Res 56 1996 794 801